November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S. launch of Mynx Control Vascular Closure Device (VCD). It integrates active extravascular sealing and bioresorbability properties with a next-generation delivery system to maximize predictability, safety, and ease of use in sealing 5-7 French femoral arterial access sites. Vascular closure devices reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional procedures.
The Mynx Control VCD features a deployment system that is designed for predictable deployment and ease of use. It will be available in 5 French as well as 6/7 French sizes. Highlights of this new system include:
• Sheath catch that is compatible with the procedural sheath;
• Tension indicator that provides visual confirmation of device position for proper sealant deployment; and
• Ergonomic handle with a 2-button deployment design to simplify procedural steps.
Leveraging the MynxGrip VCD technology, which has been used in over 2 million interventional cases worldwide, the Mynx Control VCD utilizes a dual-mode active sealing mechanism. This allows the sealant to interlock with the contours of the arterial wall, expanding to fill the tissue tract and create a matrix structure for clot formation. With all closure components resorbing within 30 days, nothing is left behind. The Mynx VCD technology has shown it can to reduce surgical complications, expedite recovery, shorten hospital stays and increase patient comfort.[1-5]
For more information: cardinalhealth.com
References:
November 14, 2025 
